



# #AskAboutAsthma 2022: Children & young people's asthma update for primary care

Babies, Children and Young People's Transformation – London

#### Chair: Dr. Oliver Anglin


Clinical Director for CYP Transformation - NHSE (London); Clinical Lead for Children and Young People - North Central London CCG; Clinical Lead for Children and Young People - Camden Directorate; GP (Hampstead Group Practice)



#### **Joining instructions and Teams etiquette**



You'll automatically be muted with camera off during the webinar



Use the group chat feature to ask questions and please like any questions that you would like answered.



This session is being recorded. A link will be available on the HLP website with any slides

# #AskAboutAsthma 2022 – primary care webinar



7<sup>th</sup> October, 12:30 – 13:30 Children & young people's asthr

Children & young people's asthma update for primary care

Торіс	Speaker
<ul> <li>Chair: Dr. Oliver Anglin</li> <li>Clinical Director for CYP Transformation - NHSE (London)</li> <li>Clinical Lead for Children and Young People - North Central London CCG</li> <li>Clinical Lead for Children and Young People - Camden Directorate</li> <li>GP (Hampstead Group Practice)</li> </ul>	
Primary care update - how to do a good annual review, inhaler check	<ul> <li>Dr. Will Carroll</li> <li>Consultant Paediatrician</li> <li>Honorary Reader in Child Health</li> <li>RCPCH Officer for Research</li> <li>Deputy Clinical Tutor</li> <li>Editor-in-Chief Paediatrics and Child Health</li> <li>NIHR - Clinical Research Scholar Staffordshire Children's Hospital at Royal Stoke</li> </ul>
Who should be referred to severe asthma services?	<ul> <li>Dr. Louise Fleming</li> <li>Clinical Reader, Imperial College London</li> <li>Paediatric respiratory consultant, Royal Brompton Hospital</li> </ul>
Difference in diagnosing viral wheeze and asthma?	<ul> <li>Dr. lan Sinha</li> <li>Consultant respiratory paediatrician, Alder Hey Children's Hospital</li> </ul>



#### **Dr Will Carroll** Consultant Respiratory Paediatrician & Reader in Child Health



#### PLEASE get it right

#### **PLAN** 2 OS LUNG FUNCTION and **EXAMINATION ADHERENCE** are still magic words! SYMPTOMS/SABA

{No matter how old you are!}

e

#### **ENVIRONMENT**

## **Conflicts of Interest**

- Dr Carroll has received funding for research studies from AstraZeneca and Trudell Medical International
- Dr Carroll is Chief Investigator on a Novartis inhaler study
- Dr Carroll is working with Chiesi on data concerning recycling of inhalers
- Dr Carroll has received speaker fees and/or honoraria for participation in advisory board work from GSK, Orion and Novartis

#### Conflicts of Interest



#### Children's voices



#### What do children and young people say?

We need more help at school to feel safe and supported with our asthma care. We need to have GPs and local hospitals who know how to look after us when we go for appointments or for emergency care. Specialist hospitals look after us really well, but sometimes the information they say doesn't get to or isn't understood by our local services.

Children and young people in clinic told us that what they wanted from GPs was a care plan that looks at helping with medication doses, that everyone can see whether in A&E or in clinic, and to have a GP or a specialist nurse who knows a lot about asthma.


When we go into hospital for an emergency we want to get medicines on arrival, to see a specialist, and to know what is going on and who is helping me. Having more help and training for our schools and our friends and family is also really important to help us to be able to do fun stuff and stay safe.

More from children and young people  $\rightarrow$ 

https://stateofchildhealth.rcpch.ac.uk/evidence/long-termconditions/asthma/

## You have been doing a great job!


Rate of emergency admissions to hospital for asthma for children and young people



#### Asthma kills children



## The UK is lagging behind (and not catching up)




http://www.youngpeopleshealth.org.uk/wp-content/uploads/2019/02/NT-AYPH-adolescent-health-report\_WEB-200219.pdf

#### Before I begin...

Please consider carefully (and quietly):

What are the six **biggest risk factors** for death from asthma in childhood?



#### Unseen... and unheard?

Please consider carefully (and quietly):

What are the six **biggest risk factors** for death from asthma in childhood?



## **U**nrecognised Risk


In CYP, poor recognition of risk of adverse outcome was found to be an important avoidable factor in 7/10 (70%) children and 15/18 (83%) young people in primary care, and in 2/7 (29%) children and 3/9(33%) young people in secondary care.

Royal College of Physicians

> Why asthma still kills The National Review of Asthma Deaths (NRAD)


Confidential Enguiry report May 2014

## Things you need to do: PLEASE




## "How is your asthma?"

Scary. Hard. Exhausting. Overwhelming. Bad. Stopping me running. Makes me feel left out. Upsating. Makes me sad. Tiring. Frustrating Drum I Cuable. Makes me feel different Divic Lt Depressing. Relentless. Poorly controlled. Hard to manage. Unsafe. Limiting. Crushing. Excluding. Worrying. Very bad. Isolating. Unfair. Expensive. Time-consuming.




RCP3Q


#### GINA (5Q)




ACT/cACT




Pinnock H, et al. Prim Care Respir J. 2012 Sep;21(3):288-94. doi: 10.410. PMID: 22751737






#### Who should I ask?



Adapted from Orell-Valente JK et al. Pediatrics 2008,122:e1186-e1192

## Lung function/FeNO

- Poor correlation between asthma symptoms and lung function
- Frequently identifies CYP with poor perception of symptoms
- Can help to provide objective evidence of improvement/need for change



## Examination

- Part of the art of medicine
- Red flags?

- Wheezy or wet?
- Nose
- Skin
- Eyes



## Adherence

Takes it often	Takes it often
Takes it well	Takes it badly
Takes it rarely	Takes it rarely
Takes it well	Takes it badly

#### What do you teach your patients?

# How to use their inhalers NACAP Audit

#### How to dispose of them?

How to tell when they are empty?



#### How Do Patients Determine That Their Metered-Dose Inhaler Is Empty?\*

Bruce K. Rubin, MD, MEngr, FCCP; and Lolly Durotoye

*Study objective:* To evaluate how patients determined that pressurized metered-dose inhaler (pMDI) canisters were empty and to measure pMDI depletion under different circumstances in the laboratory.

Setting: Most of the study was performed in a university research laboratory.

*Participants:* Fifty consecutive patients attending the Brenner Children's Hospital Asthma Center were initially questioned regarding pMDI use, and they demonstrated their use of the inhaler. *Measurements and results:* Of the 50 children and parents questioned, 74% did not know how many actuations were in their canisters, and all used their pMDI until they could not longer "hear" the medication when actuating. Only half shook the canister before actuating. In the laboratory, chlorofluorocarbon (CFC) canisters typically had 86% more actuations than the nominal dose, and hydrofluoroalkane (HFA) canisters had 52% more. Canister flotation was ineffective in identifying when a pMDI was depleted, and water obstructed the valve opening 27% of the time. For CFC inhalers, shaking the pMDI before firing increased the number of actuations per canister (p = 0.009 [vs not shaking]), but this was not true for HFA inhalers. *Conclusions:* If patients are not taught to recognize when a pMDI is empty, they may continue to use the medication for up to twice the intended duration. Until accurate dose counters are added to pMDIs, counting the number of doses administered is the only accurate method with which to tell when the canister should be discarded. *(CHEST 2004; 126:1134-1137)* 

Key words: adherence; aerosol therapy; asthma medication; dose counters; hydrofluoroalkane propellants; pressurized metered-dose aerosol


Abbreviations: CFC = chlorofluorocarbon; HFA = hydrofluoroalkane; pMDI = pressurized metered-dose inhaler

#### **Environment**

## It matters to your patients

# It matters to their families

#### It matters



Carroll W, et al. Saving our planet one puff at a time. Lancet Resp Med May 1 2022



## Do you have <u>some</u> questions?



#### PLEASE get it right

#### **PLAN** 2 OS LUNG FUNCTION and **EXAMINATION ADHERENCE** are still magic words! SYMPTOMS/SABA

{No matter how old you are!}

e

#### **ENVIRONMENT**



## Which Children Should be Referred to a Severe Asthma Service?

Dr Louise Fleming Reader, Imperial College London Consultant Respiratory Paediatrician, Royal Brompton Hospital

Imperial College London



Royal Brompton and Harefield hospitals

## Conflict of interest disclosure

Affiliation / Financial interest	Commercial company
Grants/research support:	Asthma UK: Joan Bending, Evelyn Bending, Mervyn Stephens and Olive Stephens Memorial Fellowship; NIHR (EME); Asthma UK Centre for Applied Research
Honoraria or consultation fees:	Novartis, Chiesi, Astra Zeneca, Teva
Participation in a company sponsored bureau:	Astra Zeneca, Boehringer Ingelheim, Novartis, Synexus, GSK, Sanofi, Respiri UK

All fees paid directly to my institution

#### **Member of GINA Science Committee**

## Overview

- Why refer?
- Indicators of poor control
- Key questions
- What can a severe asthma service offer?

## Why Refer?


Optimise management of children with poor asthma control

Access to a specialist multidisciplinary team

#### Minimise risk

Access to additional tests / assessments

#### Risk



## **Indicators of Poor Control**


Indicators of poor asthma control

- Asthma attack
- Hospital admission / ED attendance
- ≥6 SABA inhalers per year
- ACT / cACT score <20

### Why is Control Poor? Three key questions

- Is it asthma?
- Are all the symptoms due to asthma?
- Why is control so poor?

### Is it Asthma? Diagnostic Evaluation



### Are All Symptoms Due to Asthma? Assessment of Co-Morbidities and Asthma Mimics

#### **Primary Care**

- Hay fever / rhinitis (nasal examination and treatment)
- Obesity lifestyle advice
- Dysfunctional breathing (history)


#### Secondary Care

- Hay fever / rhinitis (nasal examination and treatment)
- Allergy testing (SPTs / splgEs)
- Obesity lifestyle advice, dietician
- Dysfunctional breathing (breathing pattern assessment)

Specialist Severe Asthma Service


- Hay fever / rhinitis (nasal examination and treatment)
- Allergy testing (SPTs / splgEs)
- Obesity lifestyle advice, dietician
- Dysfunctional breathing (specialist physiotherapist)
- Cardio-pulmonary exercise test, CLE
- Polysomnography

### Why Is Control Poor? Assessment of Modifiable Factors / Severity




### **SPECIALIST SEVERE ASTHMA SERVICE**

#### Assessment pathway for children with problematic severe asthma



### "Solving" Difficult Asthma



### Adherence check

- Prescription check GP & hospital records
- ICS adherence and number of SABA inhalers


	Medication	Strength	Total daily dose	Number of days 1 inhaler should last	May-16	Jun-16	Jul-16	Aug-16	Sep-16	Oct-16	Nov-16	Dec-16	Jan-17	Feb-17	Mar-17	Apr-17	Total	%	uptake
ICS (ICS/LABA)	seretide	125	1 puffs BD	60 DAYS	:	1			1				1	L				3	50%
Prednisolone																			
Epien		0.3mg					4				4								
Salbutamol		100mcg			:	2	2	2	2 2	2 2	2 2	2	. 2	2		2	:	20	
Montelukast		4mg					2	8 2	.8	28	8 28	56	28	3	28	3			

• Smartinhaler monitoring

Prescription check: 20 salbutamol inhalers, 3 Seretide in past year



### Adherence Monitoring: An Essential Tool for Identifying Severe Asthma



Jochmann, Fleming Eur Respir J 2017; 50; 1700910

Adherence

### Allergen Exposure

- Exposure to allergen exacerbates asthma in sensitised individuals
- Exacerbation most likely in those with a viral illness and exposed to a sensitised allergen


Table 3 Odds ratios (95% CI) for risks factors for hospital admission using constructed variable\* (mutually exclusive catergories), univariate and multivariate (adjusted for use of ICS and duration of asthma)

ci) p vo o 9.2) 0.47 d expos	1.75 (0.3 to 11.7)							
d expo	bre baa	virue						
Sensitised and exposed and virus detected OR 22.7 (4.6 – 112.5)								
0.9) 0.00	0.9 (0.8-1.1)	0.3						
	0.9] 0.00							

neither sensitised nor virus infected (± exposed)

†Median (range) in years; OR refers to decreased risk with each additional year.


• Mattress covers led to a reduction in exacerbations in those with asthma and HDM sensitised







### Smoking




#### Not just cigarettes

- History
- Home visit
  - Evidence of smoking
- Urinary cotinine
- CO monitor



#### **INCREASING PREVALENCE**




The prevalence of water pipe use among students has increased dramatically in Jordan and the USA.










### Psychosocial issues



Fleming, Bush in press

### Safeguarding

- Neglect
  - Poor adherence
  - Inappropriate environment
- Exaggerated or fabricated symptoms
  - Secondary gain
  - Fabricated and induced illness
  - Deliberately withholding treatment
- Place of safety
- Emotional abuse



**Psychosocial** 

### Structured MDT Assessment

#### **First Clinic Appointment**

- •Respiratory Consultant
- •Clinical nurse specialist (CNS)
- •Physiotherapist
- •Psychologist
- Specialist pharmacist

#### **Assessments:**

- •Spirometry and bronchodilator response (BDR)
- •FeNO (induced sputum)
- Blood eosinophils
- •Symptom score (Asthma Control Test ACT/ Childhood Asthma Control Test C-ACT)
- •Quality of life (Paediatric Asthma Quality of Life Questionnaire PAQLQ)
- •Psychosocial questionnaire and Paediatric Index of Emotional Distress (PI-ED)
- •Urinary or salivary cotinine
- •Allergy testing (skin prick tests (SPTs), specific IgEs to aeroallergens (sIgEs), total IgE)
- •Other bloods (drug levels)
- •Short Synacthen test

#### Adherence monitoring:

Issued with an Electronic monitoring Device (EMD)

#### **Additional Information**

- •Local team
- •Primary care (including prescription check)

School



#### **Follow up Appointment**

- •Respiratory Consultant
- •CNS
- •(Physiotherapist)


#### **Assessments:**


- •Spirometry and BDR
- •FENO (induced sputum)
- Asthma control (ACT/C-ACT)
- •Quality of life (PAQLQ)

#### Adherence monitoring:


•EMD data downloaded

Referral pathway to a specialist (tertiary) severe asthma service: child aged 5 – 16 years with problematic asthma





### Asthma Pathway Components



Slide courtesy of Dr Richard Chavasse

## Conclusion

- Consider referral in all children with indicators of poor control
- Address three key questions
  - 1. Is this asthma?
  - 2. Are all the symptoms due to asthma?
  - 3. Why is control so poor?
- Important to carry out a systematic assessment and address potentially modifiable factors
- Specialist asthma service provides access to MDT, further assessments and access to biological treatments
- Teamwork and working in partnership with young people and their families is essential



### Acknowledgements





Joan Bending, Evelyn Bending, Mervyn Stephens and Olive Stephens Memorial Fellowship



FNSNF Schweizerischer Nationalfonds zur Förderung der wissenschaftlichen Forschung







Asthma UK Centre for Applied Research



# The difference between diagnosing asthma and viral wheeze

Ian Sinha Consultant respiratory paediatrician Alder Hey Children's Hospital, Liverpool



### Structure

- Diagnosing asthma in children (and the usual cautionary tales)
- Phenotypes of preschool wheeze
- A simple framework: more like asthma, or more like viral wheeze?

# Cough and wheeze ≠ asthma

#### CT findings in 67 children with 'asthma' (Wajid, Sinha 2016, ERS)

Findings	n (%)
Normal/ non-specific	57 (83%)
Bronchiectasis	5 (7%)
Bronchiolitis obliterans	2 (3%)
Structural tracheal problems	2 (3%)
Allergic alveolitis	1 (1%)

All alternative diagnoses strongly suspected on history

iansinha@liv.ac.uk

#### Bronchoscopy in children with 'asthma'



Wet cough




Neutrophilia



Dyspnoea

iansinha@liv.ac.uk

Cystic fibrosis Primary ciliary dyskinesia Bacterial bronchitis















# Are the respiratory symptoms a marker of something non-medical?

- Housing
- Pollution
- Smoking
- Nutrition
- Stress

• Consider antenatal and postnatal factors




#### HEADS IT'S ASTHMA, TAILS IT'S NOT!



iansinha@liv.ac.uk @iansinha


# Back to basics...

Cough Wheeze Dyspnoea Variability Atopy




iansinha@liv.ac.uk







Wheezing prevalence



Yes	Does the child have interval symptoms when they do not have viral infections?	No
Yes	Are the exacerbations severe and/or frequent?	No
Yes	Are any of the following markers present?: Atopy (personal or first-degree relative) Eosinophilic inflammation (serum, FeNO, BAL) Sensitisation (IgE/RAST/Skin Prick Test)	No
		Less like estame mere lik

More like preschool asthma

Less like asthma, more like preschool episodic wheeze

### Summary

- 50% of preschoolers wheeze 50% of these grow out of it; 50% of them grow into children with asthma
- Think about the symptomology and presentation this may not be viral wheeze or asthma!
- Three questions:
  - What are they like on a good day?
  - Are there severe and/or frequent exacerbations?
  - Is there any suggestion of Type 2 inflammation?